PATENT CLAIM ANALYSIS

Application Number: 16412091
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "210210"]

Abstract:
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Claim (Index 10):
A method for treating cancer in a patient in need thereof, the method comprising (a) determining that the cancer is associated with a KRas G12C mutation (e.g., a KRas G12C-associated cancer); and (b) administering to the patient a therapeutically effective amount of a compound according to any one of  claim 1  or  2 .

Metadata:
- Claim Count in Document: 20.0
- Percentile: 100.0
- Lexical Diversity: 1.6
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15814279', '16191190', '16173726', '13586814', '13948342']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7998280738302079
- 35 USC 102 Novelty (BERT): 0.6141708144273813
- Combined Prediction Score: 0.7812623478899253
- Mean Citation Score: 450.776984
- Max Citation Score: 570.5313
- Similarity Product: 520.3985096081972

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test